To date, Vabysmo is approved in more than 100 countries for nAMD and diabetic macular edema (DME), and in more than 60 countries for macular edema following retinal vein occlusion (RVO). More than ...

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche has announced new data at the Euretina Congress in Paris from its AVONELLE-X and SALWEEN studies of Vabysmo (faricimab), confirming the the ...

Xenotransplantation, leveraging genetic engineering and CRISPR, offers a promising solution to the organ shortage crisis ...

In an unprecedented leap in scientific discovery, a new lifeform has been constructed using a mere 57 genetic instructions.

Researchers from the Belgian Federal Institute Sciensano, as part of the DARWIN project, have developed a proof-of-concept ...

By leveraging the Protein Mutation Effect Predictor (ProMEP), AI-AncBE4max, a high-performance Cas9 variant with eight ...

Many scientific discoveries are serendipitous—the result of chance. Seeing evolution in action in a cheese cave turned out to ...

The integration of oncolytic viruses (OVs) with immunotherapy is reshaping the landscape of tumor treatment, offering new hope for patients.

Genetically engineered cell lines used in biomedical research have long been prone to misidentification and unauthorized use, wasting billions of dollars each year and jeopardizing critical scientific ...

With the aim of streamlining the regulatory process for biopharmaceutical manufacturers engaged in vaccine, recombinant DNA, ...